The EMA And EU Expansion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The EMA And EU Expansion
In addition to coordinating centralised authorisation procedures for medicines, the EMA is responsible for a number of other tasks, and must rely heavily on the involvement of the EU member states and the countries of the European Economic Area. The greatest challenge faced by the agency, however, is the continuing expansion of the EU.


Pharmaceutical Technology Europe
Volume 23, Issue 6

References

1. Europa, "The 2004 enlargement: the challenge of a 25-member EU", Europa website 2007. http://europa.eu/ (accessed 12 May 2011)

2. I. Eckhart, "The European Medicines Agency (EMEA) — from Research to Therapies", Bridges 11 2006. http://www.ostina.org/ (accessed 12 May 2011)

3. EMA, "European Union enlargement. EMA", EMA website 2011. http://www.ema.europa.eu/ (accessed 12 May 2011)

4. Anon., "EMEA in the European system", Bull. Soc. Sci. Med. 1/2004, 87–92 (2004).

5. IDABC, "EUDRANET: European Telecommunication Network in Pharmaceuticals (EMEA)", Europa website 2004. http://ec.europa.eu/ (accessed 12 May 2011)

6. EMA, "EU Regulatory Network - Challenges and Opportunities for Croatia", EMA website 2008. http://www.emea.europa.eu/htms/euenlargement (accessed 12 May 2011)

7. EMA, "Successful Rijeka conference strengthens EU-Croatian cooperation on medicines regulation", EMA website 2008. http://www.ema.europa.eu/ (accessed 12 May 2011)

8. H. Prange, Queen's Papers on Europeanisation No 8/2002 (2002). http://www.qub.ac.uk92/ (accessed 12 May 2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here